The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F18%3AN0000169" target="_blank" >RIV/00098892:_____/18:N0000169 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/18:00104094 RIV/00216208:11110/18:10375352 RIV/00216208:11120/18:43916151 RIV/00216208:11130/18:10375352 and 9 more

Result on the web

<a href="https://link.springer.com/article/10.1007%2Fs00277-017-3218-0" target="_blank" >https://link.springer.com/article/10.1007%2Fs00277-017-3218-0</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00277-017-3218-0" target="_blank" >10.1007/s00277-017-3218-0</a>

Result language

angličtina

Original language name

The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database

Original language description

The aim of this study is to assess the incidence, risk factors, and outcome of biopsy-proven transformation in follicular lymphoma (FL) patients in the rituximab era. Transformation was analyzed in 1233 patients with initially diagnosed FL grades 1-3A, identified between 2002 and 2012 in the prospectively maintained Czech Lymphoma Study Group database. Only patients with histologically proven transformation (HT) were included. HT occurred in 58 cases at a median of 3.0 years from the initial FL diagnosis; the HT rate was 4% at 5 years. Transformation occurred most frequently at the first relapse (84% patients). Median OS from the HT was 2.5 years (95% CI 0.4-4.6) and 6-year OS with HT was shorter compared to all FLs (60 vs. 83.9%; 95% CI). A bulky tumor (≥ 10 cm), increased lactate dehydrogenase, age ≥ 60 years, and International Prognostic Index (intermediate/high risk), but not Follicular Lymphoma International Prognostic Index, were associated with transformation (p < 0.05). In the first line, 70% of patients received rituximab (including 36% rituximab maintenance), 57% CHOP-like regimens, and 2.6% of patients were treated with fludarabine-based therapy, whereas 11% of patients were watched only. The patients treated with R-CHOP in the first line (n = 591) showed the transformation rate at 5 years of 4.23% (95% CI 2.52-5.93); subsequent rituximab maintenance (n = 276) vs. observation (n = 153) was associated with a lower transformation rate (p.033; HR 3.29; CI 1.10-9.82). The transformation rate seems to be lower than in previous series, which may be influenced by broad use of rituximab, but prognosis of HT developed during therapy continues to be poor.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

<a href="/en/project/NV16-31092A" target="_blank" >NV16-31092A: Population of Elderly Patients with Non-Hodgkin´s Lymphomas – the Analysis of Factors Affecting the Management and Outcome</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Annals of Hematology

ISSN

0939-5555

e-ISSN

1432-0584

Volume of the periodical

97

Issue of the periodical within the volume

4

Country of publishing house

DE - GERMANY

Number of pages

10

Pages from-to

669–678

UT code for WoS article

000426644800012

EID of the result in the Scopus database

2-s2.0-85040221894